Estradiol valerateCAS# 979-32-8 |
- Catalpol
Catalog No.:BCN5094
CAS No.:2415-24-9
- 2-Methoxyestradiol (2-MeOE2)
Catalog No.:BCC2228
CAS No.:362-07-2
- Estradiol Benzoate
Catalog No.:BCC4779
CAS No.:50-50-0
- Ethinyl Estradiol
Catalog No.:BCC3777
CAS No.:57-63-6
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 979-32-8 | SDF | Download SDF |
| PubChem ID | 13791 | Appearance | Powder |
| Formula | C23H32O3 | M.Wt | 356.5 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 50 mg/mL (140.25 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | [(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] pentanoate | ||
| SMILES | CCCCC(=O)OC1CCC2C1(CCC3C2CCC4=C3C=CC(=C4)O)C | ||
| Standard InChIKey | RSEPBGGWRJCQGY-RBRWEJTLSA-N | ||
| Standard InChI | InChI=1S/C23H32O3/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3/t18-,19-,20+,21+,23+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Estradiol valerate Dilution Calculator
Estradiol valerate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.805 mL | 14.0252 mL | 28.0505 mL | 56.101 mL | 70.1262 mL |
| 5 mM | 0.561 mL | 2.805 mL | 5.6101 mL | 11.2202 mL | 14.0252 mL |
| 10 mM | 0.2805 mL | 1.4025 mL | 2.805 mL | 5.6101 mL | 7.0126 mL |
| 50 mM | 0.0561 mL | 0.2805 mL | 0.561 mL | 1.122 mL | 1.4025 mL |
| 100 mM | 0.0281 mL | 0.1403 mL | 0.2805 mL | 0.561 mL | 0.7013 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Estradiol is a synthetic ester used to treat menopausal symptoms and hormone deficiencies.
- Norfloxacin lactate
Catalog No.:BCC9104
CAS No.:97867-34-0
- 8,9-Didehydro-7-hydroxydolichodial
Catalog No.:BCN6674
CAS No.:97856-19-4
- Penciclovir Sodium
Catalog No.:BCC5635
CAS No.:97845-62-0
- IMD 0354
Catalog No.:BCC4556
CAS No.:978-62-1
- Lappaconitine Hydrobromide
Catalog No.:BCN2505
CAS No.:97792-45-5
- Jasmoside
Catalog No.:BCN7552
CAS No.:97763-17-2
- 2,6-Dimethyl-3-O-methyl-4-(2-methylbutyryl)phloroglucinol
Catalog No.:BCN7356
CAS No.:97761-91-6
- 2,6-Dimethyl-3-O-methyl-4-isobutyrylphloroglucinol
Catalog No.:BCN7355
CAS No.:97761-90-5
- S186
Catalog No.:BCC5285
CAS No.:97759-16-5
- Chuanxiongzine hydrochloride
Catalog No.:BCC8147
CAS No.:97747-88-1
- Decynium 22
Catalog No.:BCC6271
CAS No.:977-96-8
- Boldenone propionate
Catalog No.:BCC8895
CAS No.:977-32-2
- 3,4'-Dihydroxy-3,5',7-trimethoxyflavan
Catalog No.:BCN4528
CAS No.:97914-19-7
- Methyl 3-carbazolecarboxylate
Catalog No.:BCN4529
CAS No.:97931-41-4
- Sophoraflavanone G
Catalog No.:BCN2987
CAS No.:97938-30-2
- Leachianone A
Catalog No.:BCN4530
CAS No.:97938-31-3
- Methyl (E)-3'-hydroxy-4'-methoxycinnamate
Catalog No.:BCN1294
CAS No.:97966-29-5
- Benzenesulfonic acid
Catalog No.:BCC8846
CAS No.:98-11-3
- 4-Aminophenylarsonic acid
Catalog No.:BCC8688
CAS No.:98-50-0
- Terpineol
Catalog No.:BCN3595
CAS No.:98-55-5
- H-Pyr-OH
Catalog No.:BCC3328
CAS No.:98-79-3
- Acetophenone
Catalog No.:BCN8300
CAS No.:98-86-2
- Nicotinamide
Catalog No.:BCN1025
CAS No.:98-92-0
- Pyrazinamide
Catalog No.:BCC4932
CAS No.:98-96-4
The effects of 6-Gingerol on reproductive improvement, liver functioning and Cyclooxygenase-2 gene expression in estradiol valerate - Induced polycystic ovary syndrome in Wistar rats.[Pubmed:28093231]
Biochem Biophys Res Commun. 2017 Mar 4;484(2):461-466.
6-Gingerol is the major pungent ingredient of ginger with anti-inflammatory and antioxidant properties. In this study, we evaluate the effects of 6-gingerol on the biochemical parameters and ovarian histological improvements in Estradiol valerate (EV) induced PCOS rats. Thirty six female Wistar rats were divided into 4 groups: control, received normal diet, PCOS control, received 4 mg/kg EV injection for 28 days and two experimental groups, received an EV injection for 28 days and followed by 6-gingerol (200 mug/kg and 400 mug/kg) for 14 days. The administration of EV led to increase body and ovarian weights, abnormality in serum sex steroid profile, decrease in antioxidant activity and increase in COX-2 gene expression. 6-gingerol treatments, particularly the 400 mug/kg dose, markedly attenuated these alterations. 6-gingerol showed beneficial effects in the EV induced PCOS rats via decreased expression of COX-2, restored biochemical parameters to normal and decreased of cysts in the ovaries.
Changes of The Uterine Tissue in Rats with Polycystic Ovary Syndrome Induced by Estradiol Valerate.[Pubmed:28367305]
Int J Fertil Steril. 2017 Apr-Jun;11(1):47-55. Epub 2016 Nov 11.
BACKGROUND: Polycystic ovary syndrome (PCOS) is one of the most common hormonal disorders that can lead to irregular menstrual cycles and hyperandrogenism. Reduced levels of progesterone and increased estrogen in these women can perpetually stimulate the endometrial tissue of the uterus. In this study, we assess the effect of PCOS induction by Estradiol valerate (EV) in a rat model. MATERIALS AND METHODS: In this experimental study, adult female Wistar rats that weighed approximately 200 g were divided into control, sham, and experimental groups (n=6 per group). The experimental group received subcutaneous injections of 2 mg EV for induction of PCOS. We confirmed the presence of PCOS in the experimental group rats. Rats from all groups were subsequently killed, after which their uteri were removed and fixed for histological and cytological analyses. The uterine tissue sections were stained with hematoxylin and eosin (H&E) and iron hematoxylin (iron-H). We examined epithelium height, thickness of the uterus wall, and frequency of the mitotic cells. The data were assessed at alpha=0.05. RESULTS: Uterine tissue findings from the experimental group showed significant increases in the height of the uterus luminal epithelium, the thickness of the uterus wall, and the frequency of eosinophils in the endometrial stroma. We observed an increased frequency of mitotic cells in the experimental group in both luminal and glandular epithelia of the uterus. An increased rate of the glandular epithelium region was noticeable and significant. CONCLUSION: Induction of PCOS by EV could change the proliferation rate in the endo- metrial tissue of the uterus.
Continuation rates, bleeding profile acceptability, and satisfaction of women using an oral contraceptive pill containing estradiol valerate and dienogest versus a progestogen-only pill after switching from an ethinylestradiol-containing pill in a real-life setting: results of the CONTENT study.[Pubmed:27695365]
Int J Womens Health. 2016 Sep 15;8:477-487.
BACKGROUND: Oral contraceptives are still associated with high discontinuation rates, despite their efficacy. There is a wide choice of oral contraceptives available, and the aim of this study was to assess continuation rates, bleeding profile acceptability, and the satisfaction of women in the first year of using a contraceptive pill containing Estradiol valerate and dienogest (E2V/DNG) versus a progestogen-only pill (POP) in a real-life setting after discontinuing an ethinylestradiol-containing pill. METHODS AND RESULTS: In this prospective, noninterventional, observational study, 3,152 patients were included for the efficacy analyses (n=2,558 women in the E2V/DNG group and n=592 in the POP group (two patients fulfilled the criteria of the efficacy population, but the used product was not known). Women had been taking an ethinylestradiol-containing pill >/=3 months before deciding to switch to the E2V/DNG pill or a POP. Overall, 19.8% (n=506) of E2V/DNG users and 25.8% (n=153) of POP users discontinued their prescribed pill. The median time to discontinuation was 157.0 days and 127.5 days, respectively. Time to discontinuation due to bleeding (P<0.0001) or other reasons (P=0.022) was significantly longer in the E2V/DNG group versus the POP group. The E2V/DNG pill was also associated with shorter (48.7% vs 44.1%), lighter (54% vs 46.1%), and less painful bleeding (91.1% vs 73.7%) and greater user satisfaction (80.7% vs 64.6%) than POP use, within 3-5 months after switch. CONCLUSION: The E2V/DNG pill was associated with higher rates of continuation, bleeding profile acceptability, and user satisfaction than POP use and may be an alternative option for women who are dissatisfied with their current pill.
Corifollitropin stimulation in combination with GnRH-antagonists after estradiol valerate pre-treatment. A pilot study on patientfriendly IVF.[Pubmed:27729967]
Facts Views Vis Obgyn. 2015 Dec 28;7(4):223-230.
OBJECTIVE: To demonstrate the feasibility of scheduling an IVF cycle, without disadvantages, in the new patient friendly stimulation protocol using the long acting Corifollitropin Alfa, in combination with GnRH-antagonist protection and GnRH-agonist triggering. STUDY DESIGN: Two groups of ten patients were admitted in the study. Both received the same stimulation protocol with Corifollitropin Alfa in combination with GnRH-antagonist protection. After ultrasound evaluation on day 7 individually dosed Menopur was added. For triggering final oocyte maturation GnRH-agonists were used. The only difference between the two groups was that in the study group, Estradiol valerate 4 mg/day was given from day 25 of the preceding cycle for a period of 10 days, thus postponing the start of follicular growth. RESULTS: Scheduling the IVF stimulation by the administration of Estradiol valerate 4 mg/day did not influence the hormonal curves, nor the embryological results in comparison to patients with the same stimulation, starting their stimulation at the beginning of menstruation. In this pilot study four out of ten patients turned out to be pregnant, demonstrating an acceptable pregnancy rate. CONCLUSION: The combination of Estradiol valerate 4 mg/day pre-treatment with the novel combination of Corifollitropin Alfa stimulation with GnRH-antagonist protection, individually topped off with Menopur, and triggered with GnRH-agonist proved to be a safe, patient-friendly (limited number of injections in comparison to classical IVF) (Patil, 2014) and efficient alternative to classical IVF stimulation protocols, allowing patients - and doctors - to schedule the treatment cycle to their convenience.
